GlassScriptPhysician profile
Phat D Hoang
NPI 1306838511
$80,053.09
in general payments reported to CMS, 2019-2025
59 companies · $7,997 in 2025
The $7,997 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,638 · 2021: $14K · 2022: $10K · 2023: $14K · 2024: $13K · 2025: $7,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $7,770 · Travel and Lodging: $3,203 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,930.00 |
| Food and Beverage | $7,770.22 |
| Travel and Lodging | $3,202.74 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $65,383.01 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $2,013.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,223.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,102.45 | 2019-2025 | Jardiance |
| Abbott Laboratories | $1,094.68 | 2019-2025 | Assurity, Proclaim, Jot Dx |
| Glaxosmithkline, LLC. | $1,093.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $901.89 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $836.47 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $826.76 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $518.99 | 2023-2025 | Gemtesa, Brovana |
| Bayer Healthcare Pharmaceuticals INC. | $512.66 | 2021-2025 | |
| Astellas Pharma US INC | $499.77 | 2019-2025 | Veozah |
| Pfizer INC. | $352.90 | 2019-2025 | |
| Amarin Pharma, INC. | $322.97 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $295.30 | 2019-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phat Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.